AM
Therapeutic Areas
Apellis Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pegcetacoplan (Systemic) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Approved |
| Pegcetacoplan (Intravitreal) - SYFOVRE | Geographic Atrophy (GA) Secondary to AMD | Approved |
| Pegcetacoplan (Intravitreal) | Geographic Atrophy (GA) Secondary to AMD (Japan) | Phase 3 |
| APL-3007 | Undisclosed Ophthalmology Indication | Discovery/Preclinical |
| Undisclosed Programs | Neurological Diseases | Research |
Leadership Team at Apellis Pharmaceuticals
CF
Cedric Francois
Co-Founder, Chief Executive Officer & President
PD
Pascal Deschatelets
Co-Founder & Chief Scientific Officer
CB
Caroline Baumal
Chief Medical Officer
KB
Kelley Boucher
Chief People Officer
MD
Mark DeLong
Chief Business & Strategy Officer
LM
Leslie Meltzer
Chief Research & Development Officer
NN
Nur Nicholson
Chief Technical Operations Officer
TS
Timothy Sullivan
Chief Financial Officer
DW
David Watson
General Counsel
GC
Gerald Chan
Chairman of the Board